Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?

Current Vascular Pharmacology

Volumn 11, Issue 3, 2013, Pages 293-298

  Torsney, Evelyn ^a   Pirianov, Grisha ^a   Cockerill, Gillian W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aneurysms; Diabetes; Fibrates; High density lipoproteins; Peroxisome proliferator activator receptors; Thiazolidin ediones

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; RETINOID X RECEPTOR; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANTIINFLAMMATORY ACTIVITY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, HDL; MOLECULAR TARGETED THERAPY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84878641215     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311030003     Document Type: Review

References (53)

1. Johansson G, Nydahl S, Olofsson P, Swedenborg J. Survival in patients with abdominal aortic aneurysms. Comparison between operative and non-operative management. Eur J Vasc Surg 1990; 4: 497-502.
2. Choksy S, Wilmink A, Quick C. Ruptured abdominal aortic aneurysms in Huntingdon district: a 10 year experience. Ann R Coll Surg Engl 1999; 81: 27-31.
3. Budd J, Finch D, Carter P. A study of the mortality of ruptured abdominal aortic aneurysms in a district community. Eur J Vasc Surg 1989; 3: 351-354.
4. Population estimates. Office for National Statistics Population Estimates Group; 1999.
5. Scott RA, Wilson NM, Ashton HA, Kay DN. Is surgery necessary for abdominal aortic aneurysm less than 6 cm in diameter? Lancet 1993; 342: 1395-1396.
6. Darling R, Messina C, Brewster D, Ottinger L. Autopsy study of unoperated abdominal aortic aneurysms. The case for early resection. Circulation 1977; 56: 161-164.
7. Sterpetti AV, Cavallaro A, Cavallari N, et al. Factors influencing the rupture of abdominal aortic aneurysms. Surg Gynaecol Obstet 1991; 173: 175-178.
8. Collaborative Aneurysm Screening Group. A comparative study of the prevalence of abdominal aortic aneurysm in the United Kingdom, Denmark and Australia. J Med Screen 2001; 8: 46-50.
9. Svensjo S, Bjorck M, Gurtelschmid M, Djavani Gidlund K, Hellberg A, Wanhainen A. Low prevalence of abdominal aortic aneu-rysm in 65 year old Swedish men indicates a change in epidemiology of the disease. Circulation 2011; 124: 1118-23.
10. Lederle FA, Nelson DB, Joseph AM. Smokers relative risk for aortic aneurysm compared with other smoking-related disease: a systematic review. J Vasc Surg 2003; 38: 329-334.
11. Lederle FA, Johnson GR, Wilson SE, et al. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Prevalence and associations of abdominal aortic aneurysm detected through screening Ann Intern Med 1997; 126: 441-449.
12. Jamrozik K, Norman PE, Spencer CA, et al. Screening for abdominal aortic aneurysm: lessons from a population-based study. Med J Aust 2000; 173: 345-350.
13. Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening programme: validation and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160: 1425-1430.
14. Blancard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysms:results of a case-control study. Am J Epidemiol 2000; 151: 575-583.
15. Karanjia PN, Madden KP, Lobner S. Coexistence of abdominal aortic aneurysm in patients with carotid stenosis. Stroke 1994; 25: 462-465.
16. Lederle FA, Larson JC, Margolis KL, et al. Abdominal aortic aneu-rysm event in the women's health initiative: cohort study. BMJ 2008; 337: a1724.
17. Kanagasabay G, Gajraj H, Pointon L, Scott RA. Co-morbidity in patients with abdominal aortic aneurysm. J Med Screen 1996; 3: 201-210.
18. Simoni G, Pastorino C, Perrone R, et al. Screening of abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg 1995; 10: 207-210.
19. LaMorte WW, Scott TE, Menzoian JO, Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship of cardiovascular risk factors. J Vasc Surg 1995; 21: 422-431.
20. Shantikumar S, Aijan R, Porter KE, Scott DJA. Diabetes and the abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2010; 39: 200-207.
21. Lederle FA, Larson JC, Margolis KL, et al. Abdominal aortic aneu-rysm event in the women's health initiative: cohort study BMJ 2008; 337: a1724.
22. Norman PE, Davis TM, Le MY, Golledge J. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connec Tiss Res 2007; 48: 124-131.
23. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysm in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J 2008; 29: 665-672.
24. Miyama N, Dua MM, Yeung JJ, et al. Hyperglycaemia limits experimental aortic aneurysm progression. J Vasc Surg 2010; 52: 975-983.
25. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000; 355: 1008-1010.
26. Marx N, Bourcier T, Sukova GK, Libby P, Plutzsky J. PPAR gamma activation in human endothelial cells increases plasmino-gen activator inhibitor type-1 expression: PPAR gamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 546-551.
27. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. PPAR gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-1103.
28. Marx N, Sukova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR gamma: differentiation-dependent PPAR gexpression and reduction of MMP-9 activity through PPAR gamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
29. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferators-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168-1178.
30. Keen HL, Ryan MJ, Beyer A, et al. Gene expression profiling of potential PPAR target genes in mouse aorta. Physiol Genomics 2004; 18: 33-42.
31. Marx N, Froehlich J, Siam L, et al. The anti-diabetic PPAR gamma-activator rosiglitazone reduces MMP9 serum level in type-2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.
32. Ricote M, Wilson TM, Kelly CJ, Glass CK. The peroxisome prolif-erators-activator receptor-gamma is a negative regulator of macro-phage activation. Nature 1998; 391: 79-82.
33. Yue TL, Chen J, Bao W, et al. In vivo myocardial protection from ischaemia/reperfusion injury by the peroxisome proliferators-activator receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-2594.
34. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 1995; 96: 354-360.
35. Walker AB, Chattington DB, Buckingham RE, Williams G. Thia-zolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453.
36. Diep QN, Mabrouk ME, Cohn J, et al. Structure, endothelial function, cell growth and inflammation in blood vessels of Angiotensin II-infused rats: role of peroxisome proliferators-activated receptor gamma. Circulation 2002; 105: 2296-23302.
37. Jones A, Deb R, Torsney E, et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 2009; 119: 3125-3132.
38. Golledge J, Cullen B, Rush C, et al. Peroxisome proliferators-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 2010; 210: 51-56.
39. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
40. Ji Y, Liu J, Wang Z, Liu N, Gou W. PPAR gamma agonist, rosigli-tazone, regulates antiotensin II-induced vascular inflammation through the TLR4-dependent signalling pathway. Lab Invest 2009; 89: 887-902.
41. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-jun N-terminal Kinase. Nat Med 2005; 11: 1330-1338.
42. Lu H, Rateri DL, Cassis LA, Daugherty A. The role of the renin-angiotensin system in aortic aneurysmal diseases. Curr Hypertens Rep 2008; 10: 99-106
43. Song JS, Kim CH, Heo JY, Cho YS. Rosiglitazone reduces a wide range of proinflammatory profiles in synovial fibroblast SW982 under spheroid culture. Immunol Lett 2010; 131: 81-88.
44. Khandouni N, Delerive P, Berrebi-Bertand I, Buckinham RE, Stels B, Bril A. Rosiglitazone, a peroxisome proliferators-activated receptor-gamma, inhibits the Jun NH2-terminal kinase activated protein I pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51: 1507-1514.
45. Morrison A, Yan X, Tong C, Li J. Acute Rosiglitazone treatment is cardioprotective against ischemia/reperfusion injury by modulating AMPK, Akt, and JNK signaling in non-diabetic mice. Am J Physiol Heart Circ Physiol 2011; 301: H895-H905.
46. Weber SM, Scarim AL, Corbett JA. PPAR gamma is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2004; 286: E329-E336.
47. Pirianov G, Waddington SN, Lindström TM, Terzidou V, Mehmet H, Bennett PR. The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J(2) delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse. Endocrinology 2009; 15: 699-706.
48. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazoldinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 17: 342.
49. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myo-cardial infarction and death from cardiovascular cases. N Eng J Med 2007; 356: 2457-2471.
50. MacDonald MR, Petrie MC, Home PD, et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care 2011; 34: 1394-1396.
51. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators, Ger-stein HC, Mohan V, Avezum A, Bergenstal RM, Chiasson JL, Gar-rido M, et al. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 2011; 54: 487-495.
52. Takagi H, Manabe H, Kawai N, Goto S-N, Umemoto T. Serum high-density and low-density lipoprotein cholesterol is associated with abdominal aortic aneurysm presence: a systematic review and meta-analysis. Int Angiol 2010; 29: 371-374.
53. Golledge J, van Bockxmeer F, Jamrozik K, McCann M, Normal PE. Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol 2010; 105: 1480-1484.